Exempting RNI in Post-BCS pN1 Breast Cancer Patients Who Have Undergone Taxane-Based Chemotherapy

Exempting RNI in Post-BCS pN1 Breast Cancer Patients Who Have Undergone Taxane-Based Chemotherapy

For most patients, postoperative radiotherapy plays a crucial role. Some early-stage breast cancer patients require prophylactic regional lymph node irradiation (RNI) in addition to whole-breast irradiation (WBI). However, the survival benefit of RNI for patients with 1-3 positive axillary lymph nodes (pN1) remains uncertain. Therefore, it's necessary to evaluate the impact of RNI on the prognosis of pN1 breast cancer patients receiving systemic therapy. At the 2024 ASCO Conference, Korean researchers initiated the KROG 1701 study (Abstract 577) to explore this issue. "Oncology Frontier" invited Professor Yanxia Zhao from Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, to interpret and comment on this study.
Standardized Diagnosis and Treatment with Innovative Breakthroughs, Ushering in a Golden Era for China’s Hematologic Oncology Field

Standardized Diagnosis and Treatment with Innovative Breakthroughs, Ushering in a Golden Era for China’s Hematologic Oncology Field

From July 5 to 7, 2024, the highly anticipated 2024 Annual Progress Seminar on Chinese Clinical Oncology (BOC) and Best of ASCO 2024 China was grandly held in Guangzhou. The conference focused on the "Annual Research Advances in Chinese Clinical Oncology 2023," selected by the Chinese Society of Clinical Oncology (CSCO), aiming to delve into the latest research achievements in China's oncology field. Given the actual situation of cancer incidence in China, the conference specially invited authoritative experts in the field of oncology to comprehensively and deeply interpret outstanding papers from the 2024 ASCO meeting across various oncology disciplines. During the conference, Oncology Frontier - Hematology Frontier invited Professor Jun Zhu from Peking University Cancer Hospital for an exclusive interview to share his profound insights and unique academic perspectives on the conference.
ASCO International Perspective | Professor Samuel R. Denmeade: Biomarkers for Bipolar Androgen Therapy in mCRPC

ASCO International Perspective | Professor Samuel R. Denmeade: Biomarkers for Bipolar Androgen Therapy in mCRPC

The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. In a recent late-breaking abstract (LBA) report, Professor Samuel R. Denmeade from Johns Hopkins University School of Medicine shared the specific results of the TRANSFORMER trial. This randomized trial targeted abiraterone-pretreated metastatic castration-resistant prostate cancer (mCRPC) patients, aiming to identify blood biomarkers. "Oncology Frontier" had the opportunity to interview Professor Samuel R. Denmeade to highlight the potential benefits and future directions of bipolar androgen therapy (BAT), a new treatment approach.
Breaking Through – Promising Results from Phase I Study of KSD-101 Dendritic Cell Vaccine in Treating EBV-Positive Hematologic Malignancies

Breaking Through – Promising Results from Phase I Study of KSD-101 Dendritic Cell Vaccine in Treating EBV-Positive Hematologic Malignancies

Epstein-Barr virus (EBV) infection is widespread among adults, yet there is no standard treatment for EBV-positive hematologic malignancies, leading to poor patient outcomes. At the 29th Annual Meeting of the European Hematology Association (EHA), Professor Chunrui Li from Tongji Hospital of Huazhong University of Science and Technology presented the results of her team’s Phase I exploratory trial of the KSD-101 dendritic cell vaccine in treating EBV-related hematologic malignancies. This study brings new hope for treating these diseases. Oncology Frontier-Hematology Frontier interviewed Professor Li to delve into this innovative research and discuss the potential impact of KSD-101 on the future of hematologic malignancy treatment.
EHA 5-Minute Interview | Professor Minghui Duan: Latest Advances in Myelofibrosis Treatment

EHA 5-Minute Interview | Professor Minghui Duan: Latest Advances in Myelofibrosis Treatment

Myeloproliferative neoplasms (MPNs) are a group of clonal hematopoietic stem cell disorders, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF). At the 29th European Hematology Association (EHA) Annual Meeting held in Madrid, Spain, from June 13 to 16, 2024, notable advancements were made in MPN research. Oncology Frontier-Hematology Frontier invited Professor Minghui Duan from the Department of Hematology, Peking Union Medical College Hospital, to introduce and provide an in-depth review of two significant studies on myelofibrosis treatment. We hope Professor Duan's insights will help us understand the research progress in this field and provide important references for future research and treatment.
Rare Cause of Splenic Infarction with Cholestasis-Related Liver Failure: A Case of Diffuse Large B-Cell Lymphoma

Rare Cause of Splenic Infarction with Cholestasis-Related Liver Failure: A Case of Diffuse Large B-Cell Lymphoma

To help clinical hepatologists broaden their horizons and enrich their practical experience, the Hepatology Digest journal has invited Professor Shanhong Tang's team from the Department of Gastroenterology at General Hospital of Western Theater Command to create the "Liver Challenging Cases" column. This column compiles classic cases encountered by Professor Tang’s team over years of clinical practice and will periodically include complex or rare cases from renowned academic journals. The focus is on elucidating diagnostic and therapeutic approaches for various liver diseases, providing valuable clinical insights for colleagues.
APACC On-site Report | Dr. Ye Zhang: “Pay it Forward” – A New Strategy to Increase STD Testing Rates

APACC On-site Report | Dr. Ye Zhang: “Pay it Forward” – A New Strategy to Increase STD Testing Rates

In the era of 5G, the consumption and entertainment habits of sexually active young people have changed significantly, including activities such as drinking coffee, shopping, watching movies, and taking selfies. It is essential to continuously explore and improve strategies for testing and preventing sexually transmitted diseases (STDs) that are tailored to the times and local conditions. At the recent 9th Asia Pacific AIDS & Co-infections Conference (APACC 2024), Dr. Ye Zhang from the Kirby Institute at the University of New South Wales, Australia, presented "Innovations in Implementation Strategies of Delivery Models," introducing the "Pay it Forward" strategy and sharing more insights in an interview with Infectious Diseases Frontier.
Dr. Brigitte Quenum: Breaking the “isolated island” model and integrating resources to address HIV prevention and control challenges in Asia and the Pacific

Dr. Brigitte Quenum: Breaking the “isolated island” model and integrating resources to address HIV prevention and control challenges in Asia and the Pacific

Recently, at the 9th Asia-Pacific AIDS& Co- Infections Conference 2024 (APACC 2024), Dr. Brigitte Quenum, UNAIDS Regional Office for Asia and the Pacific, delivered a speech entitled "Challenges & Success in the Region" and in an interview with Infectious Disease Frontier,she introduced the challenges and solutions of HIV/AIDS prevention and treatment in the Asia- Pacific region, with particular emphasis on breaking the "isolated island" model of government or community fighting alone and achieving the integration of multiple resources.
Professor Jun Cheng: New Strategy for Clearing HBV cccDNA, but Further Validation Needed

Professor Jun Cheng: New Strategy for Clearing HBV cccDNA, but Further Validation Needed

Clinical cure of chronic hepatitis B (CHB), also known as functional cure, is achieved when patients remain HBsAg negative after stopping treatment, with or without the presence of anti-HBs, HBV DNA levels below the detection limit, and normal liver biochemical indicators. However, HBV covalently closed circular DNA (cccDNA) may still persist in the nuclei of liver cells in these patients. Therefore, clearing HBV cccDNA remains a major obstacle to achieving complete virological cure of CHB. Recently, at the 17th National Clinical Conference on Liver Diseases held in Shenyang, "Hepatology Digest" invited Professor Jun Cheng from Hebei Wutu Pharmaceutical Co., Ltd. to discuss the clearance of HBV cccDNA and other related issues.
Xinghai Forum: Professors Hong Hu and Yuntao Wei Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer

Xinghai Forum: Professors Hong Hu and Yuntao Wei Discuss CDK4/6 Inhibitors in Adjuvant Therapy for HR+ Breast Cancer

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors have brought transformative breakthroughs to the clinical treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer patients. The combination of CDK4/6 inhibitors and endocrine therapy has become the standard regimen for HR+/HER2- locally advanced and metastatic breast cancer. In the adjuvant treatment phase for early-stage breast cancer, CDK4/6 inhibitors have also shown positive results and have been approved for indications. The 2024 ASCO conference presented multiple advancements in the adjuvant treatment of HR+/HER2- early-stage breast cancer with CDK4/6 inhibitors. At the recent 5th Comprehensive Cancer Treatment Academic Conference of the Xinghai Medical Forum, Oncology Frontier invited Professor Hong Hu from Shenzhen People's Hospital, and Professor Yuntao Wei from Liaoning Cancer Hospital & Institute to elaborate on and discuss the research progress of CDK4/6 inhibitors in adjuvant therapy for HR+ early-stage breast cancer.